Dangerous Drugs

Nearly 30 percent of the drugs approved by the U.S. Food and Drug Administration between 2001 and 2010 were later found to be harmful, according to the Journal of the American Medical Association. Most Americans take at least one prescription drug; it’s unfortunate and unacceptable that thousands will suffer every year as a direct result of the medicine they relied on for safe treatment.

Stueve Siegel Hanson advocates for the victims of dangerous drugs and defective medical devices. Through class-action lawsuits and mass tort actions, we hold major pharmaceutical manufacturers and distributors accountable.

Our experience and results in these cases have been recognized throughout the legal community; Stueve Siegel Hanson attorneys are routinely selected by judges to serve in leadership positions in national lawsuits involving dangerous drugs. Among our recent appointments:

  • Norman Siegel was selected for leadership in the Proton Pump Inhibitor (PPI) litigation;
  • Todd Hilton was selected for leadership in the Risperdal litigation; and
  • Abby McClellan was selected for leadership in the Taxotere litigation.

Our current drug and device cases are listed below; contact information for each case is on the specific page. We stand ready to help you and your family.

 Drug and Device Cases:

  • Actos - Type 2 diabetes drug linked to increased risk of bladder cancer
  • Byetta and Januvia - Type 2 diabetes drugs linked to increased risk of pancreatic cancer
  • DePuy and Zimmer - Hip replacement recalls
  • IVC Filters (C.R. Bard and Cook) - Inferior Vena Cava (IVC) filter recalls
  • Risperdal - Antipsychotic drug linked to male breast growth (gynecomastia)
  • Taxotere - Chemotherapy drug used in breast cancer treatments linked to permanent hair loss
  • Testosterone Therapy (Low-T) - Used to treat low testosterone in men, linked to an increased risk of heart attack and stroke
  • Transvaginal Mesh – Mesh product used in certain pelvic surgeries, linked to a number of serious medical complications
Jump to Page